Welcome to Sprout Pharmaceuticals Medical Affairs Portal

This page includes links to publications about our products, which may discuss both approved and unapproved uses, formulations, or treatment regimens. The content is provided solely for informational purposes and is not intended to promote any specific product or indication. Results from a single study may not reflect the overall results obtained across the product development. Sprout Pharmaceuticals does not recommend use of its products in any manner inconsistent with the approved Prescribing Information.

Search Medical Information

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Our scientific content is non-promotional, evidence-based, and scientifically balanced. It is updated regularly, through rigorous internal medical review, to reflect new information.

Publications: This section contains educational resources on information relating to Addyi (Flibanserin 100mg).

Efficacy of flibanserin in women with hypoactive sexual desire disorder: Results from the BEGONIA trial

Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial

Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the DAISY study

Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women: Efficacy of Flibanserin in the VIOLET Study.

Open-label extension study of flibanserin in women with hypoactive sexual desire disorder

Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial

Flibanserin for hypoactive sexual desire disorder: an open-label safety study

Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder

Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder

Publications: This contains educational resources on information relating to Addyi (Flibanserin).

Efficacy of flibanserin in women with hypoactive sexual desire disorder: Results from the BEGONIA trial

Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial

Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the DAISY study

Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women: Efficacy of Flibanserin in the VIOLET Study.

Open-label extension study of flibanserin in women with hypoactive sexual desire disorder

Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial

Flibanserin for hypoactive sexual desire disorder: an open-label safety study

Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder

Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder